Description:

The EvAluation of TaBlo In-CLinic and In-HOme; ODM derived from: https://clinicaltrials.gov/show/NCT02460263

Link:

https://clinicaltrials.gov/show/NCT02460263

Keywords:
Versions (1) ▾
  1. 3/28/19
Copyright Holder:
See clinicaltrials.gov
Uploaded on:

March 28, 2019

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility End Stage Renal Disease NCT02460263

Eligibility End Stage Renal Disease NCT02460263

Inclusion Criteria
subject has end stage renal disease (esrd) adequately treated by maintenance dialysis achieving a kt/v ≥ 1.2 and has been deemed stable for at least three months by his/her treating nephrologist.
subject has a well-functioning and stable vascular access that allows a blood flow of at least 300 ml/min.
Exclusion Criteria
life expectancy less than 12 months from first study procedure.
subject has had a recent major cardiovascular adverse event within the last 3 months.
subject has new york class iii or iv congestive heart failure, or ejection fraction less than 30%.
subject with fluid overload due to intractable ascites secondary to liver cirrhosis.
subject has uncontrolled blood pressure.
subject is intolerant to heparin.
subject is seroreactive for hepatitis b surface antigen.
subject has an active, life-threatening, rheumatologic disease.
subject has a history of adverse reactions to dialyzer membrane material.
subject is expected to receive an organ transplant during the course of the study.
subject has a life-threatening malignancy actively receiving treatment that would prevent successful completion of the study protocol.